#Sweden #Orexo #AmorphOX #Uppsala #OX640

Orexo to Present Clinical Data for OX640 at the EAACI Congress

In a significant update for the pharmaceutical and allergy treatment landscape, Orexo AB has announced its upcoming participation in the 2025 EAACI Congress. Scheduled for
June 13-16 in Glasgow, UK, this event will spotlight Orexo's innovative therapeutic solution—OX640, a nasal rescue medication designed specifically for treating severe allergic reactions, including anaphylaxis.

Unveiling OX640

OX640 utilizes the proprietary AmorphOX® technology, making it a unique powder-based formulation of epinephrine. This innovative delivery mechanism promises a rapid onset of action in patients at risk of severe allergic incidents. The powerful combination aims not only to provide immediate relief but also avoids the logistical challenges associated with traditional injectable adrenaline products.

Presentation Highlights

At the congress, Dr. Anne K. Ellis, a prominent figure in allergy and immunology and an advisor to Orexo, will present compelling data from the OX640-002 clinical study. This study is noteworthy as it demonstrated that under conditions of allergic rhinitis, epinephrine absorption occurred significantly faster compared to normal states. The implications of this finding are particularly vital for patients experiencing simultaneous airway symptoms during an allergic reaction, as the rapid absorption translates to a faster therapeutic effect.

In addition to Dr. Ellis's oral presentation, Orexo's Senior Vice President and Head of Research and Development, Robert Rönn, will showcase a scientific poster that provides detailed stability data regarding OX640. Rönn expressed excitement for the congress, emphasizing, "With our powder-based drug delivery technology, we are positioned to offer robust data from our second clinical study of OX640 and a leading stability profile. I have full confidence that OX640 can become a convenient, effective, and reliable rescue medication for those facing severe allergic reactions."

The Impact of OX640

OX640 stands to change the landscape of allergy treatments significantly. As a nasal epinephrine powder, it provides not only a means for acute treatment of severe allergic reactions but also a needle-free alternative with an extended shelf-life and flexibility in storage. This is particularly beneficial for allergic patients who often experience real-time challenges when managing such life-threatening conditions.

Clinical Study Overview

The OX640-002 study, is recognized as a 4-period crossover design that involved 30 otherwise healthy individuals with seasonal allergic rhinitis. Conducted during the allergy season, the study meticulously monitored various parameters, including plasma levels of epinephrine, blood pressure, and heart rate following the administration of different doses of OX640 juxtaposed against standard intramuscular epinephrine administration. Importantly, at least one treatment period included the administration of allergens that induced acute allergic rhinitis, further substantiating the findings of the rapid medication absorption under stress conditions.

About EAACI and Orexo

The European Academy of Allergy and Clinical Immunology (EAACI) is an authoritative global association actively innovating in the realm of suffering from allergic and immunological diseases. It brings together over 16,000 health professionals from 125 countries, fostering collaboration and advancements in treatment approaches.

Orexo, founded in Sweden, carries 30 years of extensive experience focusing on formulating improved pharmaceuticals that align with unmet medical needs. The company primarily offers innovative treatments for opioid use disorder while actively exploring solutions in various therapeutic areas with distinguished partners. In 2024, Orexo reported SEK 590 million in total net sales, showcasing significant growth and productivity.

For those interested in learning more about Orexo and its innovative products, further details can be found on Orexo's official website. Engage with them on social platforms like X, LinkedIn, and YouTube for the latest updates.

As the 2025 EAACI Congress approaches, the anticipation surrounding Orexo's presentations and findings promises to spotlight the evolving landscape of allergy treatment and the potential of OX640 in revolutionizing care for patients at risk of severe allergic reactions.